thalidomide has been researched along with Hemolysis in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hemolysis: The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Multiple laboratory tests and a rigorous review of the samples, time of collection, and laboratory results revealed that only samples collected shortly after lenalidomide administration showed hemolysis." | 7.81 | Transiently Pink-Tinged Serum in a Patient With Multiple Myeloma and Anemia Undergoing Lenalidomide Treatment. ( Sofronescu, AG; Wedel, W, 2015) |
| "Multiple laboratory tests and a rigorous review of the samples, time of collection, and laboratory results revealed that only samples collected shortly after lenalidomide administration showed hemolysis." | 3.81 | Transiently Pink-Tinged Serum in a Patient With Multiple Myeloma and Anemia Undergoing Lenalidomide Treatment. ( Sofronescu, AG; Wedel, W, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fozza, C | 1 |
| Pardini, S | 1 |
| Giannico, DB | 1 |
| Targhetta, C | 1 |
| Di Tucci, AA | 1 |
| Dessalvi, P | 1 |
| Angelucci, E | 1 |
| Dore, F | 1 |
| Fattizzo, B | 1 |
| Zaninoni, A | 1 |
| Nesa, F | 1 |
| Sciumbata, VM | 1 |
| Zanella, A | 1 |
| Cortelezzi, A | 1 |
| Barcellini, W | 1 |
| Wedel, W | 1 |
| Sofronescu, AG | 1 |
| COHLAN, SQ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia: a Quasi Randomized Control Trial in a Tertiary Care Hospital in Bangladesh[NCT06098014] | Phase 3 | 60 participants (Anticipated) | Interventional | 2023-03-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thalidomide and Hemolysis
| Article | Year |
|---|---|
FETAL AND NEONATAL HAZARDS FROM DRUGS ADMINISTERED DURING PREGNANCY.
Topics: Abnormalities, Drug-Induced; Anti-Bacterial Agents; Anticoagulants; Antimetabolites; Antineoplastic | 1964 |
3 other studies available for thalidomide and Hemolysis
| Article | Year |
|---|---|
Dramatic erythroid response to low-dose thalidomide in two patients with transfusion independent thalassemia and severe post-transfusional alloimmune hemolysis.
Topics: Aged; Anemia, Hemolytic; Antibodies, Monoclonal, Murine-Derived; Blood Transfusion; Female; Hemolysi | 2015 |
Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Erythrocytes; Hemolysis; Huma | 2015 |
Transiently Pink-Tinged Serum in a Patient With Multiple Myeloma and Anemia Undergoing Lenalidomide Treatment.
Topics: Anemia; Antineoplastic Agents; Female; Hemolysis; Humans; Lenalidomide; Middle Aged; Multiple Myelom | 2015 |